Overview:
Multiple myeloma is a cancer form that develops in a type of white blood cell known as plasma cell. Healthy plasma cells normally help the body fight infections by creating antibodies that detect virus cells and attack them, whereas in multiple myeloma, cancerous plasma cells gather in the bone marrow and prevents it from forming healthy blood cells. The formation of these myeloma cells caused erythrocyte, fewer leukocyte, and platelet cell formation that damages immune system. Multiple myeloma symptoms include enlarged organs, gastrointestinal problems, kidney damages, loss of appetite, bone pain, rapid weight loss, and fever. Multiple myeloma is the third most common type of blood cancer followed by lymphoma and leukaemia.
Request Here Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/839
Drivers:
Frequent launch of novel, safe, and effective medications for myeloma multiple myeloma, increasing development of microRNA drugs and emerging nanomedicine platform are the factors expected to augment growth of the global multiple myeloma drugs market. The market is expected to witness a strong growth due to introduction of monoclonal antibodies and Histone Deacetylase (HDAC) inhibitors. Doctors are favouring the biological treatment of monoclonal antibodies such as DARZALEX and EMPLICITI due to established clinical profile.
Moreover, increasing aging population with rising number of multiple myeloma cases, and the need for new efficient drugs are boosting the investment in the R&D , which in turn is expected to propel growth of the global multiple myeloma drugs market.
Regional analysis:
The global multiple myeloma market is regionally divided into North America, Latin America, Europe, Middle East, Asia Pacific and Africa.
Among regions, North America is expected to witness strong growth in the multiple myeloma drugs market over the forecast period, owing to increasing cases of multiple myeloma. For instance, in 2017, American Cancer Society estimated around 30,280 new cases are expected to be registered in the U.S. comprising 17,490 cases in men and 12,790 cases in women, and multiple myeloma is expected to cause 12,590 deaths. Moreover, the North America is expected to see robust growth in the market of multiple myeloma due to introduction of various new treatment for multiple myeloma. For instance, the introduction of DARZALEX, FARYDAK, and NINLARO.
Furthermore, Europe is also expected to witness strong growth in the global market of multiple myeloma drugs market, due to frequent approvals of drug rates, presence of major market players and supporting reimbursement.
Get PDF Brochure with Latest Insights: https://www.coherentmarketinsights.com/insight/request-pdf/839
Market taxonomy:
By distribution channel:
- Hospital Pharmacy
- Retail Pharmacy
- ePharmacies
By drug type:
- Immunomodulating agents
- Proteasome inhibitors
- Histone Deacetylase (HDAC) inhibitors
- Steroids (Corticosteroids)
- Monoclonal antibodies
Major players:
Major players active in the global multiple myeloma drugs market are Takeda Pharmaceuticals, Johnson & Johnson, Novartis, Elgene, Amgen, GlaxoSmithKline, Bristol-Meyer Squibb, Sanofi, Merck, and Acceleron Pharma.
Reasons to Purchase this Report
• Current and future of global Multiple Myeloma Drugs market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Content
Global Multiple Myeloma Drugs Market Research Report
Section 1: Global Multiple Myeloma Drugs Industry Overview
Section 2: Global Economic Impact on Multiple Myeloma Drugs Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Multiple Myeloma Drugs Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837